A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention

Immunomodulatory properties of histone deacetylase inhibitors represent a reasonable approach for acute graft-versus-host disease (aGVHD) prevention. We report a phase 2 trial evaluating panobinostat (PANO) administered over 26 weeks, starting on day −5 (5 mg orally 3 times a week) with tacrolimus i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Perez, Lia, Fernandez, Hugo, Kharfan-Dabaja, Mohamed, Khimani, Farhad, Betts, Brian, Mishra, Asmita, Ayala, Ernesto, Locke, Frederick L., Ochoa-Bayona, Leonel, Nieder, Michael, Pidala, Joseph, Achille, Alex, Powers, John, Sahakian, Eva, Thapa, Ram, Wang, Xuefeng, Anasetti, Claudio
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2021
Materias:
Transplantation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8288668/
https://ncbi.nlm.nih.gov/pubmed/34242388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2021004225
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares